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ABSTRACT 
Object. The IFN induced Jak-STAT signal alone is not sufficient to explain all the 
biological effects of IFN. The PI3-K pathways have emerged as a critical additional component of 
IFN-induced signaling. This study attempted to clarify that relationship between IFN induced 
PI3-K-Akt- mTOR activity and anti-viral action. Result. When the human normal hepatocyte 
derived cell line was treated with rapamycin (Rapa), before accretion of IFN-α, tyrosine 
phosphorylation of STAT-1 was diminished. Pretreatment of Rapa had an inhibitory effect on the 
IFN-α induced expression of PKR and p48 in a dose dependent manner. Rapa inhibited the IFN-α 
inducible IFN-stimulated regulatory element luciferase activity in a dose-dependently manner. 
However, Wortmannin, LY294002 and Akt inhibitor did not influence IFN-α inducible luciferase 
activity. To examine the effect of PI3-K-Akt-mTOR on the anti-HCV action of IFN-α, the 
full-length HCV replication system, OR6 cells were used. The pretreatment of Rapa attenuated its 
anti-HCV replication effect in comparison to IFN-α alone, whereas the pretreatment with PI3-K 
inhibitors, Wortmannin and LY294002, and Akt inhibitor did not influence IFN induced anti-HCV 
replication. Conclusion. IFN induced mTOR activity, independent of PI3K and Akt, is the critical 
factor for its anti-HCV activity. Jak independent mTOR activity involved STAT-1 phosphorylation 
and nuclear location, and then PKR is expressed in hepatocytes.  
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INTRODUCTION 
 Currently, a chronic hepatitis C virus (HCV) infection is the major cause of hepatocellular 
carcinoma worldwide (1). Therefore, an anti-HCV strategy is important for prevention of 
carcinogenesis. Advancement in the treatment of HCV by a combination of pegylated interferon 
(IFN) and ribavirin is effective in 80% of HCV genotype 2 or 3, but less than 50% of genotype 1. 
To ameliorate the salvage rate of HCV infection, new anti-HCV agents have been developed to 
inhibit the life cycle of HCV and are combined with IFN-α (2). Since IFN-α is the most basic agent 
for HCV treatment, it is necessary to improvement the salvage rate of HCV infection by clarifying 
the efficacy of IFN treatment.  
 The factors associated with a refractory response to IFN treatment are the HCV genotype, 
viral load, age, sex, fibrosis of the infected liver and metabolic factors such as insulin resistance and 
steatosis (3). Increased hepatic expression of the suppressor of cytokine signaling (SOCS) family, 
known as the Jak-STAT signal inhibitors, especially SOCS-3, is associated with non-response to 
IFN treatment (4.5). It is thought that inflammatory cytokines, such as, interleukin 6, induced by 
HCV infection can induce SOCS-3 in hepatocyte (5). SOCS-3 inhibits IFN induced tyrosine 
phosphorylation of Jak, then intra-hepatocyte IFN signal transduction is inhibited. For HCV 
survival, Jak1, Tyk2 and STAT-1,-2 signaling, which is the essential pathway for type 1 IFN induced 
anti-viral activity, becomes the attack targets from HCV. The relative lack of a viral response to IFN 
treatment is associated with blunted IFN signaling (6). HCV coding proteins also inhibit STAT-1 
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tyrosine phosphorylation (7). The cause of a refractory response to IFN treatment is thought to be 
HCV induced Jak-STAT signal inhibition.  
 Type 1 IFN is a pleiotropic cytokine which activates various intra-cellular signal pathways 
other than the Jak-STAT signal (8). Additional signaling pathways could either collaborate with 
STATs at the promoter level and contribute to the activation of the STATs plus transcription factor 
genes or function totally independent of any STAT factors, thus leading to the activation of 
transcription factor only genes (8). The Jak-STAT signal alone is not sufficient to explain all the 
biological effects of type 1 IFN. The PI3-K and p38 kinase pathways have emerged as critical 
additional component of IFN-induced signaling (8.9.10). p38, activated via IL-1β is enhanced 
STAT-1 tyrosine phosphorylation and express the anti-viral protein, PKR (9). The IFN induced 
PI3-K-Akt pathway has Jak independent activation and it is the critical signal for cell survival and 
insulin action (10), but its relationship with the anti-viral action and PI3-K-Akt pathway is still 
unclear.  
Recently, mTOR, a downstream kinase of PI3-K-Akt pathway, was shown to play a critical 
role in protein synthesis and anti-viral effects. Kaur and his colleagues reported that the IFN 
activated mTOR pathway exhibits important regulatory effects in the generation of the IFN 
responses, including the anti-encephalomyocarditis virus effect (11). The IFN-induced mTOR is 
LY294002 sensitive and does not affect the IFN-stimulated regulatory element (ISRE) dependent 
promoter gene activity. Human cytomegalovirus is inhibited by 5’-AMP-activted protein kinase 
mediated inhibition of mTOR kinase (12). In contrast, vesicular stomatitis virus is mTOR 
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dependent (13). A relationship has been reported between the replication of hepatitis virus and 
mTOR activity. p21-activated kinase 1 is activated through the mTOR/p70 S6 kinase pathway and 
regulates the replication of HCV (14). mTOR activation is dependent upon the PI3-K-Akt and ERK 
pathways. Gao and colleagues reported that HCV-NS5A protein activates the PI3-K-Akt-mTOR 
pathway and could inhibit HBV RNA transcription and reduce HBV DNA replication in HepG2 
cells (15). The activation of the N-Ras-PI3-K-Akt-mTOR pathway by HCV is required for cell 
survival and HCV replication (16). Therefore, PI3-K, Akt and mTOR activated by HCV are 
inhibitory signals of HCV replication and survival signals of HCV infected cells. Furthermore, the 
PI3-K-Akt-mTOR pathway, which is activated by HCV, is thought to be one mechanism for 
chronic HCV infection (14.15.16). However, type 1 IFN induced PI3-K, Akt and mTOR have not 
yet been fully evaluated regarding their influence on HCV replication.  
 This study investigated whether IFN-α induced the PI3-K-Akt-mTOR pathway, whether 
the Jak-STAT pathway has a relationship with the PI3-K-Akt-mTOR pathway, and, finally, whether 
IFN induced signal transduction, other than the Jak-STAT pathway, is associated with the anti-HCV 
activity.  
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MATERIALS AND METHODS 
Reagents and Cell Culture 
Recombinant human IFN-α2b was a generous gift from Schering-Plough KK (Tokyo, 
Japan). Wortmannin, LY 294002, Akt inhibitor and rapamycin were purchased from Calbiochem 
(La Jolla, CA). Hc human hepatocyte cells (Applied Cell Biology Research Institute, Kirkland, 
Washington) and HuH-7 human hepatoma cells (American Type Culture Collection, Rockville, 
Maryland) were maintained in a chemically defined medium, CS-C completed (Cell Systems, 
Kirkland, Washington) and RPMI (Invitrogen, Grand Island, New York), respectively, 
supplemented with 5% fetal bovine serum. In the pretreatment of rapamycin and chemical inhibitors 
for 3 hr, the cells were cultured in 5% RPMI, and then exchanged the medium and treated the cells 
with IFN-α2b at the indicated time. 
Cell viability assay 
The cells were measured using the colorimetric cell viability assay method. Cell viability 
was determined by the colorimetric method using a Cell Counting kit (Wako Life Science, Osaka, 
Japan). The absorbance of each well was measured at 405nm with a microtiter plate reader 
(Multiskan JX, Thermo BioAnalysis Co., Japan). After two days of 100 IU/mL IFN-α and 1000 
nmol/L rapamycin treatment, Cell viability is expressed as a percentage of the viability in standard 
media without IFN-α and rapamycin. Data were expressed as the mean ± standard deviation (SD). 
Statistical significance was assessed using Student’s t test. Statistical difference was defined as 
P<0.05. All numerical results were reported as the mean of four independent experiments. 
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Western Blotting and antibodies 
Western blotting with anti-PKR, anti-STAT-1 (Santa Cruz Biotechnology, Santa Cruz, CA), 
anti-tyrosine-701 phosphorylated STAT-1, anti-serine-727 phosphorylated STAT-1, anti-p48, 
anti-serine-437 phosphorylated Akt, anti-threonin-308 phosphorylated anti-Akt, anti-Akt, 
anti-serine-2448 phosphorylated mTOR, anti-serine-2481 phosphorylated mTOR, anti-mTOR, 
anti-JAK-1 or anti-tyrosine 1022/1023 JAK-1 (Cell Signaling, Beverly, MA) was performed as 
described previously (9). Briefly, Hc cells were lysed by the addition of a lysis buffer (50 mmol/L 
Tris-HCl, pH 7.4, 1% Np40, 0.25% sodium deoxycholate, 0.02% sodium azide, 0.1% SDS, 150 
mmol/L NaCl, 1 mmol/L EDTA, 1mmol/L PMSF, 1 μg/ml each of aprotinin, leupeptin, and 
pepstatin, 1 mmol/L sodium o-vanadate, and 1 mmol/L NaF). The samples were separated by 
electrophoresis on 8-12% SDS polyacrylamide gels and electrotransferred to nitrocellulose 
membranes, and then blotted with each antibody. The membranes were incubated with horseradish 
peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG, and the immunoreactive bands were 
visualized using the ECL chemiluminescence system (Amersham Life Science, Buckinghamshire, 
England). 
Fluorescence immunohistochemistry 
 The Hc cells were seeded onto 11-mm glass cover-slips in 24-well plates at 2.4 x105 cells 
/well. The next day, the medium was replaced with serum-free medium, and the cells were 
pretreated with 10 nmol/L or 100 nmol/L rapamycin, or vehicle, for 3 hr and then stimulated with 
100 IU/mL IFN-α for 10 min. Fluorescence immunohistochemistry was performed as described 
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previously (17). The cells were incubated with anti-tyrosine-701 phosphorylated STAT1 antibody 
for 1 hr at room temperature, washed three times in PBS, incubated with rhodamine-conjugated 
donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 1 hr, 
washed in PBS, and mounted in Vectashield Mounting Medium (Vector Laboratories Inc., 
Burlingame, CA). Nuclear staining was performed using Hoechst 33258 (Invitrogen Japan K.K., 
Tokyo, Japan). An immunofluorescence analysis was done using an Olympus BX50 microscope 
(Tokyo, Japan) and the image was captured by a Nikon DXM 1200 digital camera (Tokyo, Japan). 
Reporter gene assay 
A pISRE-Luc cis-reporter plasmid containing five copies of the ISRE sequence and the 
firefly luciferase gene and pRL-SV40 containing the SV40 early enhancer/promoter and the renilla 
luciferase gene were obtained from Clontech (San Diego, CA) and Promega (Madison, WI), 
respectively. The HuH-7 cells were grown in 24-well multiplates and transfected with 1 μg of 
pISRE-Luc and 10 ng of pRL-SV40 as a standard by the lipofection method. One day later, the cells 
were incubated in the absence or presence of varying concentrations of chemical blockers and 
IFN-α, and the luciferase activities in the cells were determined using a dual-luciferase reporter 
assay system and a TD-20/20 luminometer (Promega). The data were expressed as the relative 
ISRE-luciferase activity. 
HCV Replicon System 
OR6 cells stably harboring the full-length genotype 1 replicon, ORN/C-5B/KE (18), were 
used to examine the influence of the anti-HCV effect of IFN. The cells were cultured in Dulbecco’s 
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modified Eagle’s medium (Gibco-BRL, Invitrogen) supplemented with 10% fatal bovine serum, 
penicillin and streptomycin and maintained in the presence of G418 (300mg/L; Geneticin, 
Invitrogen). This replicon was derived from the 1B-2 strain (strain HCV-o, genotype 1b), in which 
the Renilla luciferase gene is introduced as a fusion protein with neomycin to facilitate the 
monitoring of HCV replication. After the treatment, the cells were harvested with Renilla lysis 
reagent (Promega, Madison, WI) and then were subjected to a luciferase assay according to the 
manufacturer’s protocol. mTOR gene knock down is used siRNA (Cell Signaling). 100 nmol/L 
mTOR specific and non-targeted siRNA as a control was transfected to OR6 cells in accordance 
with the appended manual. One day later, the cells were incubated in either the absence or presence 
of 10 IU/mL IFN-α. 
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RESULTS 
IFN-α induced Activity of STAT-1 is inhibited by rapamycin pretreatment 
 To attempt to clearly identify the influence of mTOR to IFN-α induced anti-viral protein 
expression rapamycin (Rapa), the specific inhibitor of mTOR, was added prior to treatment with 
IFN-α. Hc cells have been used as normal hepatocytes in previous reports (19). The Hc cells were 
incubated in the absence or presence of IFN-α with or without pretreatment with Rapa for 2 hr the 
cells were then harvested for the Western blot analysis (Fig. 1). IFN-α clearly induced tyrosine and 
serine phosphorylation of STAT-1 at 5 (Fig. 1A, lane 4) and 10 min (Fig. 1A, lane 6), respectively 
in the absence of Rapa. However, when the Hc cells were pretreated with Rapa before IFN-α 
stimulation, the levels of tyrosine and serine phosphorylated STAT-1 were clearly and rapidly lower 
than those induced by IFN-α alone 5 min after treatment in tyrosine (Fig. 1A, lane 5). Jak-1, an 
upstream protein of STAT-1, was equally phosphorylated by IFN-α with (Fig. 1B lane3) or without 
(Fig. 1B lane2) pretreatment with Rapa. The viability of the Hc cells was 1 in vehicle, 0.93±0.21 in 
IFN-α treatment and 0.88±0.34 in rapamycin treatment. No difference in the cell viability the 
among vehicle, IFN-α and rapamycin treatment was not recognized in our assay. The viability of the 
HuH-7 and OR6 cells also demonstrated no difference between the presence of IFN-α and 
rapamycin treatment and the absence thereof. 
IFN inducible gene products are diminished by pretreatment of rapamycin 
 Since pretreatment with Rapa inhibited the IFN-α induced STAT-1 activity, the 
phosphorylation of tyrosine and serine and nuclear translocation, the effect of pretreated with Rapa 
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on the IFN-α inducible gene product was examined. The protein levels of PKR, an anti-viral protein 
that acts as a mRNA translation inhibiter activated by double stranded RNA (20.21), and p48, key 
component of ISGF-3 with activated STAT-1 and -2 (22), were induced by IFN-α treatment for 3 hr 
in Hc cells (Fig. 1C, lane 1 and 2). However, pretreatment with Rapa had an inhibitory effect on 
IFN-α induced PKR and p48 in a dose dependent manner (Fig. 1C, lanes 2, 3 and 4).  
The serine 473 on Akt and serine 2448 on mTOR are phosphorylated by IFN-α 
 Because pretreatment with Rapa affected the IFN-α signaling (Fig. 1), the ability of IFN-α 
to activate the Akt–mTOR pathway was investigated. The phosphorylation of serine-2448 residues 
of mTOR and serine-473 residue of Akt by 100 IU/ml of IFN-α was detected at five min and at 60 
min after IFN-α treatment, respectively (Fig. 2A). The band intensity of serine 2448 phosphorylated 
mTOR increased at 30 min and decreased at 60 min after IFN-α treatment. In contrast, a slight band 
intensity of serine phosphorylated 473 Akt was only detected at 60 min after IFN-α treatment. In 
addition, a Western blot analysis of phosphorylated serine 2481 of mTOR and threonine 308 Akt 
was conducted under the same conditions as Figure 2A, but no bands were detected (data not 
shown). In Figure 2D, IFN-α induced Serine 2448 phosphorylated mTOR was not inhibited by 
PI3-K inhibitors (lanes 2 and 3). 
The IFN-α induced nuclear translocation of tyrosine phosphorylated STAT-1 was inhibited by 
pretreatment with Rapa 
The location of tyrosine phosphorylated STAT-1 was evaluated by fluorescence 
immunohistochemistry of cultured Hc cells (Fig. 3). The IFN-α induced nuclear translocation of 
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tyrosine phosphorylated STAT-1 was observed (Fig. 3C), but its translocation was inhibited by 
pretreatment with Rapa and the inhibition of the translocation of STAT-1 was more definitive at 
1000 nmol/L Rapa (Fig. 3E) than 100 nmol/L (Fig. 3G). 
IFN-α induced ISRE-contained promoter activity is inhibited by pretreatment of Rapa, but not by 
Wortmannin, LY294002 and Akt inhibitor 
 The influence of pretreatment of PI3-K-Akt-mTOR inhibitors on IFN-α inducible 
luciferase activity of the ISRE-containing promoter was examined. Since Hc cells were not 
sufficient for reporter gene transfection, HuH-7 cells were used in the transfection assay. HuH-7 
cells were transfected with pISRE-Luc containing five repeats of the ISRE sequence and 
pRV-SV40 as a standard and then were treated with IFN-α after 3 hr with or without pretreatment 
with Rapa, Wortmannin, LY294002 or Akt inhibitor. Rapa inhibited IFN-α inducible luciferase 
activity in a dose-dependent manner (Fig. 4 lane 2, 3 and 4). However, Wortmannin and 
LY294002, PI3-K inhibitor, and Akt inhibitor had no effect on IFN-α inducible luciferase activity 
(Fig. 4, lane 2, 5, 6 and 7).  
 The expression of IFN-α induced tyrosine phosphorylated STAT-1 was determined after 
pretreatment with Akt inhibitor and LY294002 to evaluate the result of luciferase assay (Fig. 4). 
The Hc cells were incubated under the same conditions used in Figure 4, but phosphorylated 
STAT-1 was not inhibited by the Akt inhibitor (Fig. 2B) and LY294002 (Fig. 2C). 
Rapamycin and mTOR specific siRNA, but not PI3-K inhibitor and Akt inhibitor, can cancel the 
IFN-α induced anti-HCV replicon activity. 
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 OR6 cells the full-length HCV replication system was used to examine the anti-viral effect 
of PI3-K, Akt and mTOR on IFN-α stimulation. The cells were treated with IFN-α after 3 hr in the 
presence or absence of Rapa, Akt inhibitor or PI3-K inhibitor (Fig. 5). Pretreatment with Rapa 
attenuated its anti-HCV replication effect in comparison to IFN-α alone (Fig. 5, lanes 1, 2, 3 and 4), 
whereas pretreatment with PI3-K inhibitors and Akt inhibitor did not increase the Renilla luciferase 
activity (Fig. 5, lanes 1, 2 and 5-8). We performed siRNA transfection for mTOR knock down (Fig. 
6). Although transfection efficiency of siRNA is barely 10%, IFN-α induced anti-HCV action was 
clearly inhibited in siRNA against mTOR transfected cells (lane 5) in comparison to the control 
cells (lane 6). 
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DISCUSSION 
 Rapa inhibited the IFN-α induced tyrosine and serine phosphorylation and nuclear 
translocation of STAT-1, the ISRE-promoter activity, the expression of PKR and the replication of 
HCV replicon. This suggests that the IFN induced mTOR activity, through Jak independent STAT-1 
phosphorylation, is a critical signal for IFN induced anti-HCV action. Interestingly, mTOR 
activated by IFN was PI3-K-Akt independent in this study.  
mTOR activity may have inhibitory action for HCV replication through STAT-1 
phosphorylation, but not the translation initiation action of mTOR. This study assumed that IFN 
induced PKR expression and ISRE-luciferase activity were inhibited by Rapa as the result of a 
suppression effect on IFN inducible STAT-1 activation. IFN inducible PKR contributes the 
anti-HCV action (20), and anti-HCV action of ribavirin is also attributable to its ability to 
up-regulate PKR activity (21). Previous reports revealed that the mTOR activity did not influence 
the HCV-IRES activity because the viral promoter has cap-independent translation (23). Although 
mTOR is the mRNA translational regulator through phosphorylation of a downstream target such as 
4E-BP and S6K (24), we think that the IFN induced mTOR activity influences the phosphorylation 
of STAT-1 in our study (Fig. 1). In addition, it is thought that the alternation of STAT-1 
phosphorylation by the mTOR activity influences the gene expression of anti-virus protein and IFN 
induced anti-viral action. 
In our study, serine-473 on Akt showed a delayed phosphorylation in comparison to that of 
serine-2448 on mTOR after IFN stimulation (Fig. 2A). Since serine-473 on Akt is phosphorylated 
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by mTOR/Rictor/GβL (25.26) and a PDK-1 independent pathway (25), IFN induced serine-473 
phosphorylated Akt may not involve the mTOR activity. Therefore, PI3-K inhibitor and Akt 
inhibitor had no effect on IFN inducible anti-HCV action. The pathway of mTOR activation is 
prismatic. PI-3Ks, upstream kinase of Akt and mTOR, are grouped into three classes (I-III) 
according to their substrate preference and sequence homology (27). PI3-k inhibitor, Wortmannin 
and LY294002, inhibit class I and III PI3-Ks, and to a lesser extent class II PI3-K, upstream kinase 
of Akt (27). In our study, neither PI3-K nor Akt inhibitor inhibited IFN induced ISRE luciferase 
activity and loss of HCV replication (Fig. 4 and 5). These results indicate that the IFN induced 
anti-HCV activity is mTOR dependent, but not PI3-K and Akt dependent. In the current report, the 
production of IL-1 receptor antagonist in IFN-stimulated monocytes depends on the PI3-K pathway, 
but not STAT-1 (28), and chronic myelogenous leukemia cells are differentially regulated by the 
IFN induced PI3-K-Akt-mTOR pathway with no relation to STAT-1 phosphorylation (29). Similar 
to the findings of those reports, the PI3-K-Akt pathway has been reported to be generally 
independent of the STAT activity (10). Therefore, the difference in the cell type (8) may explain the 
discrepancy between these data and our data. We therefore speculate that in hepatocytes, unlike 
lymphoid cells, IFN induced mTOR activity is not dependent on the PI3-K activity. In addition, the 
mTOR activity is not related to the STAT activity in lymphoid cells. However, in hepatocytes, the 
IFN induced mTOR activity was closely linked to the IFN induced STAT activity in our study.  
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mTOR is a serine and threonine kinase (10). Phosphorylation of STATs by mTOR occurs 
also on a serine residue, but not tyrosine (10.30). The mTOR pathway is critical for IFN-γ induced 
suppression of tyrosine phosphorylated STAT-3 in a prostate cancer cell line (31). Although this is 
not consistent with the results of our study, this also showed mTOR to be associated with tyrosine 
phosphorylation without reference to SOCS and phosphatase. In addition, in a mouse embryo 
fibroblast cell line, IFN-γ induced tyrosine and serine phosphorylation of STAT-1 is inhibited by 
Rapa (32), while in the hepatoma cell line, HLF, IFN-β stimulated STAT-1 tyrosine phosphorylation 
partially decreases by LY294002, but the effect of Rapa has not yet been studied (33). In the current 
study (31.32.33), not only STAT-1 serine phosphorylation but also tyrosine was found to be 
downstream of the IFN induced mTOR activity, however, the mechanism controlling the tyrosine 
phosphorylation of STAT-1 and the mTOR activity, remains to be elucidated. 
In conclusion, IFN induced mTOR activity, independent of PI3-K and Akt, is the critical 
factor for anti-HCV action. The Jak independent mTOR activity is therefore involved in STAT-1 
phosphorylation and nuclear location, thus resulting in the development of IFN induced anti-HCV 
protein, especially the expression of PKR, in HCV infected hepatocytes.  
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FIGURE LEGENDS 
 
Figure 1. Alteration in the distribution of IFN-α induced phosphorylated STAT-1 (A) and 
Jak-1 (B) by rapamycin and Effect of rapamycin on IFN-α-induced PKR and p48 (C) 
Hc cells were pretreated without (lanes 1, 2, 4, 6 and 8) or with 1 μmol/L Rapa (lanes 3, 5, 7 and 9). 
These Hc cells were stimulated by 100 IU/L IFN-α  (lane 2-9) for 30 min. Phosphorylated STAT-1 
at tyrosine-701 residue (upper panel) and at serine-727 residue (lower panel) were analyzed by 
Western blotting. (A). After pretreatment of 1000 nmol/L Rapa (lane 3) for 3 hr, Hc cells were 
untreated (lane 1) or treated with 100 IU/mL IFN-α (lanes 2-3) for 3 min, then phosphorylated 
JAK-1 at tyrosine-1022/1023 residue (first panel), expression of JAK-1 (second panel) were 
analyzed by Western blotting (B). Hc cells were treated with 100 IU/mL of IFN-α in the absence 
(lane 2) or of the presence of pretreatment (lane 3 and 4). Lane 1 was not treated IFN-α and 
calcineurin inhibitors. One day latter, PKR and p48 was determined by Western blotting (C). 
 
Figure 2. Effect of IFN-α on Akt and mTOR (A) and effect of Akt inhibitor (B) and LY294002 
(C) on IFN-α-induced tyrosine phosphorylated STAT-1 and Serine phosphorylated mTOR 
(D). 
Hc cells were stimulated by 100 IU/L IFN-α for 60 min. At the indicated time, the cells were 
harvested. Phosphorylated Akt at serine-473 residue (first panel), Akt (second panel), mTOR at 
serine-2448 residue (third panel) and mTOR (fourth panel) were analyzed by Western blotting. 
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After pretreatment with 5 or 20 μmol/L Akt inhibitor (lane 3 and 4, respectively) (B) and 1 or 10 
nmol/L LY294002 (lane 3 and 4, respectively) (C) for 3 hr, Hc cells were untreated (lane 1) or 
treated with 100 IU/mL IFN-α (lanes 2-4) for 5 min and phosphorylated STAT-1 at tyrosine-701 
residue (first panel), expression of STAT-1 (second panel) were analyzed by Western blotting. (D) 
After pretreatment with 100 nmol/L Wortmannin (lane 2) and 1 nmol/L LY294002 (lane 3) for 3 hr, 
the Hc cells were either untreated (lane 1) or treated with 100 IU/mL IFN-α (lanes 2-4) for 10 min 
and then were phosphorylated mTOR at Serine-2448 residue (first panel), the expression of mTOR 
(second panel) was analyzed by Western blotting. 
 
Figure 3. Inhibition of IFN-α induced nuclear translocation of phosphorylated STAT-1 by 
rapamycin. 
The Hc cells were pretreated without (A. B. C. D) or with 1000  nmol/L Rapa (E. F) or 100 nmol/L 
Rapa (G. H). After pretreatment, the Hc cells were stimulated by 100 IU/L IFN-α (C. D. E. F. G. H) 
for 30 min. Thereafter, the cells were fixed, permeabilized, processed for immunofluorescence (A. 
C. E. G) and Hoechst staining (B. D. F. H), and visualized by fluorescence microscopy. The results 
shown are from one representative experiment from a total of three performed. 
 
Figure 4. Suppression effect of rapamycin, not PI3-k inhibitors and Akt inhibitor, on 
IFN-α-induced reporter gene assay. 
 Ichikawa T., et. al., Page. 25  
HuH-7 cells transfected with reporter gene (pISRE-Luc and pRL-SV40) were either untreated (lane 
1) or pretreated with Rapa (lane 3. 4), Wortmannin (lane 5), LY294002 (lane 6) or Akt inhibitor 
(lane 7) for 3 hr, followed by IFN-α 100 IU/mL (lane 2 -7). Six hr later, the relative ISRE-luciferase 
activity (n=4) was determined as described in the MATERIALS AND METHODS. The data are 
expressed as the mean ± SD and are representative example of four similar experiments. 
 
Figure 5. Alternation of IFN-α suppressed HCV replication by rapamycin, but not PI3-K 
inhibitors and Akt inhibitor. 
OR6 cells, a full-length replicon system, were treated with 100 IU/mL of IFN-α in the absence (lane 
2) or presence of pretreatment (lane 3-8) for 3 hr. Lane 1 was not treated IFN-α alone. One day 
latter, Rennila luciferase activity was determined by luminometer (n=4). The data are expressed as 
the mean ± SD and are representative example of four similar experiments. 
 
Figure 6. Alternation of IFN-α suppressed HCV replication by siRNA against mTOR. 
The OR6 cells were transfected the siRNA against mTOR (lane 2 and 5) and the non-targeted 
siRNA (lanes 3 and 6). One day later, the cells were IFN-α treatment (lane 4-6). HCV replicon 
assay is same as Figure 5. The data are expressed as the mean ± SD and are representative example 
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